TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
Brief Summary: Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Options:
A: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
B: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
C: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability
Brief Summary: The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in subjects suffering from severe chronic low back pain (LBP) who are taking WHO Step III analgesics and show lack of tolerability. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome.

The trial will compare the effectiveness of previous analgesic treatment (WHO Step III) with that of tapentadol hydrochloride prolonged release treatment during defined periods of evaluation.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: CG5503; Type: EXPERIMENTAL; Interventions: Drug: CG5503 | Intervention Type: DRUG; Name: CG5503; Assigned to Arm(s): CG5503 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Tapentadol (CG5503); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol (CG5503) ER | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): Oxycodone | Intervention Type: DRUG; Name: Tapentadol (CG5503) ER; Assigned to Arm(s): Tapentadol (CG5503)
C: Arm Label: Tapentadol Prolonged Release; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol Prolonged Release | Intervention Type: DRUG; Name: Tapentadol Prolonged Release; Assigned to Arm(s): Tapentadol Prolonged Release
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: tapentadol (CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: tapentadol (CG5503); Assigned to Arm(s): 001

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Vitamin D and Exercise in Preventing Falls of Elderly Women
Brief Summary: The aim of the study is to investigate the effects of exercise and vitamin D supplementation on reducing falls and injuries in community-dwelling, independent-living women aged 70-79 years of age. The investigators will test the following hypothesis:

1. Exercise including strength, balance and mobility training will improve muscle functioning and body balance, and thus reduce falls by 30% compared with non-exercisers.
2. Vitamin D intake will improve muscle functioning and thus prevent falls by 30% compared with placebo.
3. Together vitamin D and exercise have a stronger influence on fall prevention than either used alone.
4. Training improves mobility functions and bone health.
5. Supervised training twice a week with daily home training will improve physical functioning thus resulting in reduced fear of falling.
6. Reduced fear of falling and improved physical functioning help older people to stay physically active, which further improve their quality of life.


Options:
A: Arm Label: observational; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise intervention | Intervention Type: OTHER; Name: Exercise intervention; Assigned to Arm(s): Exercise group
B: Arm Label: exercise with vitamin D 800 IU/d; Type: EXPERIMENTAL; Interventions: Dietary Supplement: exercise and vitamin D supplementation | Arm Label: exercise with placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: exercise and vitamin D supplementation | Arm Label: no exercise with vitamin D 800 IU/d; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: exercise and vitamin D supplementation | Arm Label: no exercise with placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: exercise and vitamin D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: exercise and vitamin D supplementation; Assigned to Arm(s): exercise with vitamin D 800 IU/d | Intervention Type: DIETARY_SUPPLEMENT; Name: exercise and vitamin D supplementation; Assigned to Arm(s): exercise with placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: exercise and vitamin D supplementation; Assigned to Arm(s): no exercise with vitamin D 800 IU/d | Intervention Type: DIETARY_SUPPLEMENT; Name: exercise and vitamin D supplementation; Assigned to Arm(s): no exercise with placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: multifactorial intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multifactorial intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Falls Prevention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Falls Prevention; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression
Brief Summary: The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.


Options:
A: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): GLYX-13, 1 mg/kg, GLYX-13, 10 mg/kg, GLYX-13, 5 mg/kg, Normal Saline
B: Arm Label: Esketamine; Type: EXPERIMENTAL; Interventions: Drug: Esketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: AZD6765 (150 mg) / Placebo; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: Placebo / AZD6765 (150 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to AZD6765 | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 (150 mg) / Placebo | Intervention Type: DRUG; Name: Placebo to AZD6765; Assigned to Arm(s): Placebo / AZD6765 (150 mg)
D: Arm Label: AZD6765 75 mg; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: AZD6765 150 mg; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: Ketamine 0.5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: 125 mL sterile NaCl 0.9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 75 mg | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 150 mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.5 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 125 mL sterile NaCl 0.9%

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease
Brief Summary: The purpose of the study is to evaluate the efficacy of stenting after dilation with or without paclitaxel-eluting balloon or atherectomy in patients with symptomatic peripheral artery disease.


Options:
A: Arm Label: Stenting; Type: ACTIVE_COMPARATOR; Interventions: Device: Stenting (Smart Stent) | Arm Label: Stenting after PEB; Type: EXPERIMENTAL; Interventions: Device: Stenting (Smart Stent), Device: Stenting after PEB (Smart Stent, Invatec) | Arm Label: Atherectomy; Type: EXPERIMENTAL; Interventions: Procedure: Atherectomy (SilverHawk device) | Intervention Type: DEVICE; Name: Stenting (Smart Stent); Assigned to Arm(s): Stenting, Stenting after PEB | Intervention Type: DEVICE; Name: Stenting after PEB (Smart Stent, Invatec); Assigned to Arm(s): Stenting after PEB | Intervention Type: PROCEDURE; Name: Atherectomy (SilverHawk device); Assigned to Arm(s): Atherectomy
B: Arm Label: Drug-eluting balloon; Type: EXPERIMENTAL; Interventions: Device: Cotavance Drug-Eluting Balloon | Arm Label: Plaque excision + drug-eluting balloon; Type: EXPERIMENTAL; Interventions: Device: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon | Arm Label: Severely Ca++ Group; Type: EXPERIMENTAL; Interventions: Device: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon | Intervention Type: DEVICE; Name: Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Drug-eluting balloon | Intervention Type: DEVICE; Name: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Plaque excision + drug-eluting balloon | Intervention Type: DEVICE; Name: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Severely Ca++ Group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Percutaneous Transluminal Angioplasty | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: LifeStent NT™ Self-Expanding Peripheral Stent | Intervention Type: OTHER; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: LifeStent NT™ Self-Expanding Peripheral Stent; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: primary stenting; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine the safety and tolerability of GT4P administered orally as a single dose, and twice daily for 7 consecutive days, to subjects with hepatic impairment with cirrhosis (Child-Pugh scores of A, B, or C) and to a gender matched and similar age control group with normal hepatic function.


Options:
A: Arm Label: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) | Arm Label: Lactulose; Type: OTHER; Interventions: Drug: Lactulose | Intervention Type: DRUG; Name: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®); Assigned to Arm(s): Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) | Intervention Type: DRUG; Name: Lactulose; Assigned to Arm(s): Lactulose
B: Arm Label: GT4P-F; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: GT4P-API; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: Ammonul; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ammonul | Arm Label: Buphenyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buphenyl | Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): GT4P-API, GT4P-F | Intervention Type: DRUG; Name: Ammonul; Assigned to Arm(s): Ammonul | Intervention Type: DRUG; Name: Buphenyl; Assigned to Arm(s): Buphenyl
C: Arm Label: HPN-100; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): HPN-100 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol Levels
Brief Summary: This study is a pilot study examining the effect of extended-release niacin (Niaspan ®) on flow-mediated vasodilation (FMD) of the brachial artery, among human immunodeficiency virus (HIV)-1 infected individuals with low high density lipoprotein (HDL). Brachial artery diameter will be measured by high-resolution ultrasound at entry and week 12 of study. The primary comparisons will be change in FMD from baseline to 12 weeks within each of the two arms. The second specific aim will be to investigate the proportion of the effect of extended-release niacin on other known cardiovascular markers.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Vitamin D 4000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): Vitamin D 4000 IU | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Active Drug (extended release niacin); Type: EXPERIMENTAL; Interventions: Drug: extended release niacin | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: extended release niacin; Assigned to Arm(s): Active Drug (extended release niacin)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins; Assigned to Arm(s): Multivitamins | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol plus calcium carbonate | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol plus calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol plus calcium carbonate; Assigned to Arm(s): A, B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of the Sentinel Node in Endometrial Cancer
Brief Summary: The purpose of this study is to investigate the relevance of sentinel node in endometrial cancer. Sentinel node is thought to reflect the status of lymph node. Only 10 to 20% of women with endometrial cancer exhibit lymph node metastasis hence systematic lymphadenectomy is questionable. In breast cancer, melanoma and vulvar cancer, sentinel node has emerged as an alternative to complete lymphadenectomy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Detection of sentinel node | Intervention Type: PROCEDURE; Name: Detection of sentinel node; Assigned to Arm(s): 1
B: Arm Label: IC Green Arm; Type: EXPERIMENTAL; Interventions: Drug: IC Green | Intervention Type: DRUG; Name: IC Green; Assigned to Arm(s): IC Green Arm
C: Arm Label: TH BSO with SNB; Type: EXPERIMENTAL; Interventions: Procedure: TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted | Arm Label: TH BSO without retroperitoneal node dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted | Intervention Type: PROCEDURE; Name: TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted; Assigned to Arm(s): TH BSO with SNB | Intervention Type: PROCEDURE; Name: TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted; Assigned to Arm(s): TH BSO without retroperitoneal node dissection
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No Lymphadenectomy (LNE) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Lymphadenectomy (LNE) | Intervention Type: PROCEDURE; Name: No Lymphadenectomy (LNE); Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Lymphadenectomy (LNE); Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial
Brief Summary: The purpose of this study is to evaluate the efficacy of Selective Retina Therapy (SRT) for treating acute idiopathic central serous chorioretinopathy (ICSC). Patients with acute symptomatic ICSC of at least 3 months duration were recruited. The patients were randomized by equal terms to SRT- (Treatment) and control group. After 3 months follow up patients of control group with persistence of disease activity were allocated to crossover group and received either SRT. Crossover group was followed up for further 3 months.

The primary outcome measure of the study are the serial changes in Early Treatment of Diabetic Retinopathy Study (ETDRS) letterscore and edema in optical coherence tomography (OCT) at 3 months. Secondary outcome measures included the proportion of eyes with complete absorption of subretinal fluid, leakage in fluorescein angiography and the systemic and ocular complications during the study at 3 months.


Options:
A: Arm Label: Intravitreal Aflibercept Injection (x4); Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Aflibercept Injection | Arm Label: Intravitreal Aflibercept Injection (x6); Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Aflibercept Injection | Intervention Type: DRUG; Name: Intravitreal Aflibercept Injection; Assigned to Arm(s): Intravitreal Aflibercept Injection (x4), Intravitreal Aflibercept Injection (x6)
B: Arm Label: Selective Retinatherapy (SRT); Type: EXPERIMENTAL; Interventions: Device: Selective Retina Therapy (SRT) | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: crossover; Type: EXPERIMENTAL; Interventions: Device: Selective Retina Therapy (SRT) | Intervention Type: DEVICE; Name: Selective Retina Therapy (SRT); Assigned to Arm(s): Selective Retinatherapy (SRT), crossover
C: Arm Label: Half-dose photodynamic therapy (PDT); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Half-dose photodynamic therapy (PDT) | Arm Label: Micropulse laser (ML) treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Micropulse laser (ML) treatment | Intervention Type: PROCEDURE; Name: Half-dose photodynamic therapy (PDT); Assigned to Arm(s): Half-dose photodynamic therapy (PDT) | Intervention Type: PROCEDURE; Name: Micropulse laser (ML) treatment; Assigned to Arm(s): Micropulse laser (ML) treatment
D: Arm Label: Low-fluence PDT with Verteporfin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Verteporfin | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: Verteporfin; Assigned to Arm(s): Low-fluence PDT with Verteporfin | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): Ranibizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Placebo-controlled Trial of Erythropoietin in ICU Patients With Traumatic Brain Injury
Brief Summary: This study seeks to determine if erythropoietin alpha (EPO) administered to adult critical care patients with moderate or severe traumatic brain injury improves neurological function assessed at six months after injury.


Options:
A: Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: epoetinum | Intervention Type: DRUG; Name: epoetinum; Assigned to Arm(s): 2
C: Arm Label: EPO group; Type: EXPERIMENTAL; Interventions: Drug: EPO group | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: EPO group; Assigned to Arm(s): EPO group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: Erythropoietin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): Placebo

Answer: D